Litcius/Paper detail

Design and synthesis of 4-anilinoquinazolines as Raf kinase inhibitors. Part 1. Selective B-Raf/B-RafV600E and potent EGFR/VEGFR2 inhibitory 4-(3-hydroxyanilino)-6-(1H-1,2,3-triazol-4-yl)quinazolines

Cheng-I Lee, Chu‐Bin Liao, Chih-Shang Chen, Fen‐Ying Cheng, Yu-Hsuan Chung, Yuchuan Wang, Sian-Yi Ciou, Wen-Yun Hsueh, Tzu-Hao Lo, Guan-Ru Huang, Hsin‐Yi Huang, Chia-Shen Tsai, Yu-Jung Lu, Shih‐Hsien Chuang, Jiann‐Jyh Huang

2021Bioorganic Chemistry18 citationsDOI

Topics & Concepts

ChemistryVEGF receptorsInhibitory postsynaptic potentialKinaseCancer researchPharmacologyBiochemistryInternal medicineMedicineQuinazolinone synthesis and applicationsMelanoma and MAPK PathwaysCancer Mechanisms and Therapy
Design and synthesis of 4-anilinoquinazolines as Raf kinase inhibitors. Part 1. Selective B-Raf/B-RafV600E and potent EGFR/VEGFR2 inhibitory 4-(3-hydroxyanilino)-6-(1H-1,2,3-triazol-4-yl)quinazolines | Litcius